Why Exact Sciences Stock Blasted Higher on Tuesday

Exact Sciences (EXAS) reported robust third-quarter results, with revenue reaching a record $851 million, a 20% year-over-year increase that significantly surpassed analyst estimates of $811 million. The diagnostics specialist also posted a surprise non-GAAP net profit of $53 million, or $0.28 per share, defying expectations of a loss, attributed to strong performance from Cologuard and Oncotype DX. Following these beats, management raised its 2025 revenue guidance to $3.22 billion-$3.24 billion and adjusted EBITDA guidance to $470 million-$480 million, prompting a nearly 4% stock gain against a declining broader market.

Analysis

Exact Sciences (EXAS) delivered a robust third-quarter performance, significantly surpassing analyst expectations across key metrics. The company reported record revenue of $851 million, a 20% year-over-year increase, which notably exceeded the average analyst estimate of less than $811 million. Furthermore, EXAS posted a surprise non-GAAP net income of $53 million, or $0.28 per share, defying consensus expectations for a $0.03 per share loss, a beat attributed to the strong performance of its Cologuard and Oncotype DX diagnostic products.

Following these strong results, management expressed confidence by raising its full-year 2025 guidance. Revenue projections were increased to a range of $3.22 billion-$3.24 billion from the prior $3.13 billion-$3.17 billion, and adjusted EBITDA guidance was lifted to $470 million-$480 million from $455 million-$475 million. The market reacted positively to the news, with EXAS stock gaining nearly 4% during a trading session where the broader S&P 500 declined by 1.2%.

This performance underscores the efficacy and market acceptance of EXAS's core diagnostic offerings, suggesting sustained demand within the healthcare diagnostics sector. The upward revision of future guidance indicates management's optimistic outlook on continued growth and profitability. The significant outperformance against a declining market highlights strong investor confidence in the company's fundamentals and strategic direction.

Key Decisions for Investors

• Investors should re-evaluate EXAS's growth trajectory and profitability potential given the significant Q3 beats and upward revised 2025 guidance.
• Monitor the sustained demand for Cologuard and Oncotype DX as key drivers for continued revenue and earnings growth.
• Assess the company's ability to maintain positive earnings momentum, especially against prior expectations of losses, and its resilience in a volatile market.